Commodore Capital LP Makes New $26.42 Million Investment in Perspective Therapeutics, Inc. $CATX

Commodore Capital LP purchased a new position in shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 6,336,782 shares of the company’s stock, valued at approximately $26,424,000. Perspective Therapeutics accounts for approximately 1.5% of Commodore Capital LP’s investment portfolio, making the stock its 22nd biggest position. Commodore Capital LP owned about 5.56% of Perspective Therapeutics at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Geode Capital Management LLC boosted its holdings in Perspective Therapeutics by 15.8% during the second quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock worth $4,758,000 after buying an additional 188,887 shares in the last quarter. JPMorgan Chase & Co. grew its position in Perspective Therapeutics by 118.4% during the second quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company’s stock worth $2,573,000 after buying an additional 405,612 shares during the period. Walleye Capital LLC increased its holdings in Perspective Therapeutics by 375.8% in the second quarter. Walleye Capital LLC now owns 187,403 shares of the company’s stock valued at $645,000 after buying an additional 148,013 shares in the last quarter. Federated Hermes Inc. increased its holdings in Perspective Therapeutics by 44.4% in the second quarter. Federated Hermes Inc. now owns 195,080 shares of the company’s stock valued at $671,000 after buying an additional 60,019 shares in the last quarter. Finally, Bank of America Corp DE lifted its position in shares of Perspective Therapeutics by 8.5% during the 2nd quarter. Bank of America Corp DE now owns 327,500 shares of the company’s stock valued at $1,127,000 after acquiring an additional 25,697 shares during the period. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Stock Performance

Perspective Therapeutics stock opened at $2.91 on Monday. Perspective Therapeutics, Inc. has a 52 week low of $1.96 and a 52 week high of $6.16. The firm’s 50-day simple moving average is $3.31 and its 200 day simple moving average is $3.90.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its earnings results on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.04. The firm had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.16 million. Perspective Therapeutics had a negative net margin of 17,982.69% and a negative return on equity of 42.33%. As a group, sell-side analysts predict that Perspective Therapeutics, Inc. will post -1.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on CATX shares. BTIG Research reissued a “buy” rating on shares of Perspective Therapeutics in a research note on Friday. Wedbush reaffirmed an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research note on Tuesday, May 5th. Eight research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $12.62.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.